EA Pharma Co., Ltd.
15
0
0
13
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Moderate Risk
Score: 45/100
13.3%
2 terminated/withdrawn out of 15 trials
86.7%
+0.2% vs industry average
13%
2 trials in Phase 3/4
23%
3 of 13 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (15)
A Study of E6011 in Participants With Active Crohn's Disease
Role: lead
A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Bioavailability, and Food-effects of EA1080 in Healthy Caucasian and Japanese Male Participants
Role: lead
A Study to Evaluate the Safety and Efficacy of AJM300 in Participants With Active Ulcerative Colitis
Role: lead
A Phase 1/2 Study of Repeated Intravenous E6011 Administration in Japanese Subjects With Crohn's Disease
Role: lead
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
Role: collaborator
A Single Intravenous Dose of E3112 in Japanese Healthy Adult Male Participants
Role: lead
Study of E6007 in Japanese Patients With Moderate Active Ulcerative Colitis
Role: lead
Study of E6011 in Japanese Subjects With Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid
Role: lead
A Single Intravenous Dose Study of E3112 in Japanese Healthy Adult Male Subjects
Role: lead
A Single Dose Study of E6130 in Japanese Healthy Adult Male Subjects
Role: lead
Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AJM347 in Healthy Male Caucasian and Japanese Subjects in the Fasted and Fed State
Role: lead
A Study to Determine the Absorption, Metabolism, and Excretion of [14C]-E6007 After a Single Oral Administration in Healthy Male Participants
Role: lead
A Study to Evaluate the Safety, Tolerability, and Pharmacokinetics in Healthy Adult Male Participants
Role: lead
General Clinical Study of AJG555 in Pediatric Patients With Chronic Constipation
Role: lead
A Phase II/III, Double-blind, Parallel Group Comparative Study of Oral Administration of NE-58095 Tablets
Role: collaborator
All 15 trials loaded